Non-animal Softgel Capsule Market Size, Share, Growth, and Industry Analysis, By Type (Starches,Pullulan,Others), By Application (Pharmaceutical,Health Supplements,Others), Regional Insights and Forecast to 2034

Non-animal Softgel Capsule Market Overview

Global Non-animal Softgel Capsule Market size is estimated at USD 16038.42 million in 2026, set to expand to USD 22670.12 million by 2035, growing at a CAGR of 3.92%.

The Non-animal Softgel Capsule Market is expanding as pharmaceutical, nutraceutical, and dietary supplement manufacturers transition from gelatin-based shells to plant-derived alternatives such as hydroxypropyl starch, pullulan, and carrageenan. Increasing vegan labeling, halal and kosher certification requirements, and regulatory preference for clean-label excipients are accelerating adoption. Non-animal softgel capsules offer improved oxidation protection, precise dosing, and enhanced bioavailability for oils, fat-soluble vitamins, and botanical extracts. More than 65% of new nutraceutical product launches in developed economies now prefer vegetarian capsule delivery systems, and over 40% of encapsulated omega-3 products introduced in recent years utilize plant-based shells. As a result, the Non-animal Softgel Capsule Market Report and Non-animal Softgel Capsule Market Analysis indicate strong formulation replacement across pharmaceuticals and supplements.

In the United States, dietary supplement consumption exceeds 75% of adult population usage annually, supporting strong adoption of non-animal capsules. Approximately 30% of new supplement SKUs launched in the U.S. specialty nutrition sector now include vegetarian or vegan labeling claims. The U.S. hosts more than 10,000 registered supplement manufacturing facilities and contract development organizations, creating significant B2B procurement demand. Sports nutrition, prenatal vitamins, and omega-3 oils account for over half of plant-based softgel usage in the country. Regulatory compliance standards and clean-label requirements from major retail chains are pushing manufacturers to replace bovine and porcine gelatin shells, strengthening domestic Non-animal Softgel Capsule Market Growth and Non-animal Softgel Capsule Market Outlook across pharmaceutical and nutraceutical industries.

Download Free Sample to learn more about this report.

Key Findings

Size & Growth

• Global size 2026: USD 16038.42 Million
• Global size 2035: USD 22670.12 Million
• CAGR (2026–2035): 3.92%

Share – Regional

• North America: 34%
• Europe: 28%
• Asia-Pacific: 30%
• Middle East & Africa: 8%

Country-Level Shares

• Germany: 22% of Europe’s
• United Kingdom: 18% of Europe’s
• Japan: 21% of Asia-Pacific
• China: 35% of Asia-Pacific

Non-animal Softgel Capsule Market Latest Trends

The Non-animal Softgel Capsule Market Trends are increasingly influenced by consumer shift toward vegan and allergen-free supplements. Manufacturers are rapidly introducing pullulan and starch-based encapsulation systems capable of withstanding humidity conditions below 40% relative moisture, significantly improving product stability compared to conventional gelatin capsules. Plant-derived shells also show oxygen permeability reduction of nearly 30%, extending shelf life of sensitive formulations such as DHA, probiotics, and coenzyme Q10. Nutraceutical brands now demand odor-masking technologies, especially for marine oils, and non-animal shells demonstrate superior odor containment in more than 60% of stability trials.

Another major Non-animal Softgel Capsule Industry Analysis trend is contract manufacturing outsourcing. Over 55% of supplement brands now depend on third-party encapsulation partners due to specialized equipment requirements including rotary die encapsulation systems operating above 3,000 capsules per minute. Additionally, pharmaceutical applications such as self-emulsifying drug delivery systems (SEDDS) increasingly use vegetarian shells for lipid-based drugs with solubility challenges. Pediatric and geriatric medication formats are adopting softgels because swallowing compliance improves by nearly 35% compared with tablets. These factors are expanding Non-animal Softgel Capsule Market Opportunities across prescription drugs, functional nutrition, and cosmeceuticals.

Non-animal Softgel Capsule Market Dynamics

DRIVER

"Rising demand for vegan and clean-label nutraceutical products"

Global plant-based product penetration has increased significantly, with vegan product launches in dietary supplements rising more than 2.5 times in the last decade. Retailers increasingly require gelatin-free labeling, especially for halal and kosher markets serving over 1.8 billion consumers worldwide. Approximately 45% of nutraceutical buyers actively check ingredient origin, driving pharmaceutical companies to reformulate existing encapsulated products. Omega-3, vitamin D3, and herbal oil formulations are primary conversion candidates. Non-animal Softgel Capsule Market Research Report findings show procurement contracts for plant-derived shells growing rapidly among contract manufacturing organizations supplying private-label supplement brands.

RESTRAINTS

"Higher production complexity and formulation limitations"

Vegetarian softgel manufacturing requires controlled humidity processing environments below 30–35% and specialized drying tunnels lasting up to 48 hours. Plant-based shell materials are sensitive to temperature fluctuations and may require modified plasticizers, increasing formulation trials. Some high-water-activity fill materials destabilize starch-based shells, limiting compatibility with certain pharmaceutical liquids. Manufacturing scrap rates can be 10–15% higher during initial scale-up compared to gelatin softgels. These technical constraints slow transition in cost-sensitive markets and affect Non-animal Softgel Capsule Market Share among small-scale supplement producers.

OPPORTUNITY

"Expansion in pharmaceutical drug delivery technologies"

Lipid-based drug formulations represent a major Non-animal Softgel Capsule Market Opportunity. Nearly 40% of newly developed drug molecules exhibit poor water solubility, encouraging pharmaceutical developers to adopt softgel encapsulation. Self-micro-emulsifying delivery systems enhance bioavailability up to threefold for certain compounds. Biopharmaceutical companies are increasingly exploring plant-derived capsules for hormones, oncology support medications, and cannabinoid-based therapeutics in regulated regions. Contract development and manufacturing organizations are installing new encapsulation lines capable of producing over 1 billion softgels annually to meet anticipated Non-animal Softgel Capsule Market Forecast demand.

CHALLENGE

"Raw material sourcing and stability consistency"

Key plant-derived inputs such as pullulan fermentation polymers and modified starch require precise microbial fermentation and purification processes. Supply chain disruptions can lead to batch variation affecting capsule elasticity and sealing integrity. Moisture migration issues may cause shell brittleness in arid climates or deformation in high humidity regions. Quality control testing often includes over 20 physical parameters including rupture strength and disintegration time. Meeting pharmaceutical-grade stability standards across diverse climates remains a critical Non-animal Softgel Capsule Industry Report challenge for global suppliers and B2B procurement managers.

Non-animal Softgel Capsule Market Segmentation

The Non-animal Softgel Capsule Market segmentation is defined by material composition and end-use adoption across regulated and consumer health industries. By type, manufacturers rely primarily on starch and pullulan shells, while specialty polysaccharide blends represent emerging alternatives. By application, demand originates from pharmaceutical drug delivery, health supplements, and specialty formulations such as cosmeceuticals and veterinary nutrition. Over 60% of product development pipelines in nutraceutical manufacturing now prioritize vegetarian encapsulation platforms, and more than 45% of contract manufacturers offer at least two plant-based capsule shell materials to meet labeling and regulatory procurement requirements in the Non-animal Softgel Capsule Market Analysis.

Download Free Sample to learn more about this report.

BY TYPE

Starches: Starch-based non-animal softgel capsules represent one of the most widely adopted materials in the Non-animal Softgel Capsule Industry Analysis due to availability, stability, and regulatory acceptance. These capsules are produced from modified corn or tapioca starch polymers, offering neutral taste and low odor migration. Approximately 42% of vegetarian softgel manufacturing globally relies on starch shell technology. The material demonstrates low oxygen permeability, helping protect oxidation-sensitive oils including omega-3, evening primrose oil, and vitamin A. Laboratory stability testing shows starch shells reduce lipid oxidation indicators by nearly 25% compared to standard gelatin formats. Starch capsules also provide consistent disintegration times within 20–30 minutes in simulated gastric fluid, aligning with pharmacopeial performance requirements.

Pullulan: Pullulan capsules are gaining significant importance within the Non-animal Softgel Capsule Market Research Report because of superior transparency, oxygen barrier properties, and premium clean-label positioning. Pullulan is produced via microbial fermentation of starch substrates and forms a highly uniform polysaccharide film. Approximately 35% of new premium supplement launches now specify pullulan shells, particularly for antioxidant-sensitive ingredients. Oxygen transmission rates of pullulan shells are nearly 50% lower than conventional gelatin, extending shelf stability for coenzyme Q10 and DHA oils. These capsules are especially valued in probiotic and herbal extract formulations because they contain no animal proteins or cross-linking risk. Pullulan capsules also show high thermal stability, remaining structurally intact up to 80°C during transportation stress testing. 

Others: The “others” category includes carrageenan blends, pectin composites, and cellulose-derived polymer softgels. Although representing a smaller portion of the Non-animal Softgel Capsule Market Size, these materials are gaining adoption in specialized formulations. Combined materials account for roughly 23% of vegetarian softgel production capacity worldwide. Carrageenan-based shells are particularly useful in high-temperature climates because they maintain elasticity even above 35°C storage conditions. Cellulose-based softgels demonstrate low moisture migration, which is beneficial for hygroscopic active ingredients such as certain botanical extracts. Pectin formulations are commonly used in sugar-free chewable softgel products designed for pediatric or geriatric use.

BY APPLICATION

Pharmaceutical: Pharmaceutical use represents a major component of the Non-animal Softgel Capsule Market Insights because softgel delivery significantly improves solubility for lipophilic drug molecules. Nearly 40% of active pharmaceutical ingredients under development exhibit poor aqueous solubility, making lipid-based delivery systems necessary. Softgel encapsulation improves dissolution and absorption by enhancing dispersion in gastrointestinal fluids. Clinical pharmacokinetic studies demonstrate bioavailability improvements of two to three times for certain fat-soluble medications when delivered in softgel form. Non-animal shells are particularly valuable for hormone therapies, antifungal agents, and anti-inflammatory compounds requiring accurate dosing. Hospitals and regulatory authorities increasingly prefer animal-free excipients to minimize allergen risks. 

Health Supplements: Health supplements account for the largest demand within the Non-animal Softgel Capsule Market Trends. More than 70% of omega-3 oils, vitamin D oils, and carotenoid formulations are delivered through softgel capsules due to superior taste masking and oxidation protection. Consumers increasingly prefer plant-based supplements, and vegetarian labeling influences purchasing decisions for over 45% of supplement buyers. Softgels also enable accurate dosing of fat-soluble vitamins, reducing variability in intake. Sports nutrition, prenatal nutrition, and immunity supplements are primary contributors. Probiotic oil suspensions, turmeric oil extracts, and herbal blends are frequently encapsulated in plant-based shells. Retailers and e-commerce channels often require gelatin-free products to meet clean-label standards. Contract manufacturers report that private-label supplement brands place recurring bulk orders for vegetarian capsules in quantities exceeding several million units per batch. The Non-animal Softgel Capsule Market Forecast shows sustained procurement demand from nutraceutical brands targeting wellness, longevity, and preventive healthcare consumers.

Others: Other applications include cosmeceuticals, veterinary nutrition, and functional food fortification. Beauty-from-within products containing collagen alternatives, hyaluronic acid oils, and ceramide oils increasingly use non-animal softgels. Ingestible skincare supplements have expanded rapidly, with more than one-third of new beauty nutrition launches utilizing plant-derived capsules. Veterinary supplements for companion animals also rely on softgels due to ease of administration and odor masking. 

Non-animal Softgel Capsule Market Regional Outlook

The Non-animal Softgel Capsule Market demonstrates diversified geographic performance across major manufacturing and consumption hubs. North America holds approximately 34% share supported by high supplement penetration and contract manufacturing infrastructure. Europe accounts for nearly 28% share due to regulatory preference for animal-free excipients and clean-label pharmaceuticals. Asia-Pacific represents about 30% share driven by large-scale nutraceutical production and expanding preventive healthcare adoption. Middle East & Africa contributes roughly 8% share with increasing halal-certified supplement demand. Together, these regions collectively represent 100% of the global Non-animal Softgel Capsule Market Share, with demand concentrated in pharmaceutical drug delivery and health supplement applications.

Download Free Sample to learn more about this report.

NORTH AMERICA

North America accounts for nearly 34% of the global Non-animal Softgel Capsule Market Share and remains the most technologically advanced production region. The United States dominates regional consumption with more than 75% of adults consuming dietary supplements annually, creating consistent demand for vegetarian encapsulation. Over 60% of nutraceutical manufacturers in the region now offer gelatin-free product lines, and nearly 45% of new product launches contain vegan labeling claims. Pharmaceutical companies are also transitioning toward plant-derived excipients to reduce allergen risk and meet regulatory procurement policies. The region hosts a dense concentration of contract development and manufacturing organizations operating high-capacity rotary die encapsulation equipment capable of producing millions of capsules daily. Omega-3 oils, vitamin D, and coenzyme Q10 supplements represent the largest product categories using non-animal softgels. 

EUROPE

Europe represents approximately 28% of the Non-animal Softgel Capsule Market Share and is strongly influenced by regulatory frameworks emphasizing excipient transparency and allergen labeling. European pharmacopoeial standards encourage non-animal excipients, and over 55% of supplement manufacturers in Western Europe now promote vegetarian certification on packaging. The region has one of the highest per-capita supplement usage rates, particularly for vitamins, mineral oils, and botanical extracts. Clean-label requirements in major retail markets have accelerated the replacement of gelatin shells. Nearly 48% of newly launched supplement formulations in Europe now use plant-based capsules. Stability studies conducted across multiple climate zones show vegetarian capsules maintain structural integrity within typical storage humidity levels between 35% and 65%. 

GERMANY Non-animal Softgel Capsule Market

Germany holds about 22% of Europe’s Non-animal Softgel Capsule Market Share and functions as a major pharmaceutical manufacturing hub. The country’s strong pharmaceutical industry infrastructure and strict quality regulations promote the adoption of plant-derived excipients. More than half of dietary supplement products sold through pharmacies include vegetarian capsule claims. German consumers demonstrate high acceptance of preventive healthcare products, particularly vitamin D, magnesium oil formulations, and herbal extracts. Manufacturers in Germany prioritize stability and standardized dosage, and laboratory evaluations show vegetarian softgels maintain consistent disintegration times under regulated testing conditions. The country also exports encapsulated supplements to neighboring European nations, supporting contract manufacturing demand. Hospitals and pediatric healthcare providers prefer non-animal formulations due to allergen reduction, and pharmaceutical research facilities continue testing lipid-based drug delivery technologies. These factors sustain Germany’s leading role within the regional Non-animal Softgel Capsule Market.

UNITED KINGDOM Non-animal Softgel Capsule Market

The United Kingdom contributes approximately 18% of Europe’s Non-animal Softgel Capsule Market Share. Consumer preference for vegan products is particularly strong, with plant-based supplement purchases increasing significantly in recent years. Retailers frequently require vegetarian certification for supplement shelf placement, encouraging manufacturers to replace gelatin capsules. More than 40% of new supplement launches in the UK include vegan or allergen-free labeling. Pharmacy chains and online wellness retailers report increased demand for omega-3 alternatives, herbal oils, and beauty nutrition products delivered through vegetarian softgels. Healthcare practitioners also recommend softgel formats for improved patient compliance, especially among elderly users managing multiple supplements daily. Contract manufacturing facilities within the UK are expanding encapsulation capacity to support private-label brands. These combined commercial and healthcare adoption patterns support consistent demand for the Non-animal Softgel Capsule Market in the United Kingdom.

ASIA-PACIFIC

Asia-Pacific accounts for nearly 30% of the Non-animal Softgel Capsule Market Share and is the fastest expanding production region. Rapid urbanization, preventive healthcare awareness, and rising supplement consumption are driving adoption. Countries such as China, Japan, South Korea, and India host large nutraceutical manufacturing bases supplying both domestic and export markets. Approximately 50% of regional supplement manufacturers now offer vegetarian capsule formulations. Production capacity is supported by large-scale encapsulation facilities operating continuous manufacturing systems. Marine oil supplements, herbal extracts, and functional oils represent primary application categories. Demand is also strengthened by cultural and dietary restrictions encouraging plant-based ingredients. Stability testing in tropical climates shows certain plant-derived capsules maintain elasticity above 30°C storage conditions, making them suitable for regional distribution. 

JAPAN Non-animal Softgel Capsule Market

Japan represents about 21% of the Asia-Pacific Non-animal Softgel Capsule Market Share. The country has a mature nutraceutical industry with widespread consumer adoption of functional foods and dietary supplements. More than two-thirds of adults regularly consume health supplements, particularly fish oil alternatives, vitamin formulations, and beauty nutrition products. Japanese manufacturers emphasize product quality, and vegetarian capsules are preferred for odor containment and dosage precision. Softgel delivery systems are commonly used in coenzyme Q10 and collagen alternative supplements. Pharmaceutical companies in Japan also apply softgel encapsulation for lipid-soluble medications and geriatric formulations. Distribution through pharmacies and specialty health stores supports consistent demand. Regulatory requirements for quality and stability testing further reinforce adoption of plant-based encapsulation technologies within the Japanese Non-animal Softgel Capsule Market.

CHINA Non-animal Softgel Capsule Market

China contributes approximately 35% of the Asia-Pacific Non-animal Softgel Capsule Market Share and functions as a major manufacturing center. The country hosts a large number of nutraceutical producers supplying both domestic consumers and export markets. Rising preventive healthcare awareness and expanding e-commerce supplement sales are increasing demand for vegetarian softgel capsules. Herbal oil extracts, traditional botanical formulations, and vitamin supplements dominate usage. Manufacturing facilities in China operate high-volume encapsulation lines capable of producing large quantities daily. Increasing regulatory oversight and quality standards are encouraging companies to adopt standardized plant-derived excipients. Export-oriented supplement producers are particularly focused on vegetarian capsules to meet international labeling requirements, supporting continued expansion of the Non-animal Softgel Capsule Market in China.

MIDDLE EAST & AFRICA

The Middle East & Africa region holds around 8% of the Non-animal Softgel Capsule Market Share. Demand is largely influenced by halal certification requirements and expanding healthcare infrastructure. Countries in the Gulf region demonstrate strong preference for animal-free excipients, and vegetarian capsules are commonly specified in procurement tenders. Approximately 60% of imported supplements in certain Gulf markets now carry halal or vegetarian labeling. Pharmaceutical distributors increasingly import plant-based softgel medications, particularly vitamin oils and nutritional therapeutics. High temperatures in the region require stable encapsulation materials, and certain plant-based capsules maintain elasticity under warm storage conditions. Healthcare awareness programs promoting preventive nutrition also contribute to rising supplement consumption. African markets are gradually adopting nutraceutical products as pharmacy networks expand. Urban populations show increasing interest in immunity and wellness supplements, especially vitamin D and omega-based formulations. Combined regulatory, cultural, and climatic factors continue to strengthen the adoption of vegetarian capsules across the Middle East & Africa Non-animal Softgel Capsule Market.

List of Key Non-animal Softgel Capsule Market Companies

• Patheon
• Catalent
• Amway
• Procaps Laboratorios
• Best Formulations
• Aenova
• Eurocaps
• Bahrain Pharma
• SaintyTec
• Captek
• Robinson Pharma
• DuPont Pharma Solutions
• Capsugel
• SIRIO

Top Two Companies with Highest Share

• Catalent: 17% share supported by extensive contract manufacturing capacity and large pharmaceutical client base worldwide.
• Aenova: 12% share driven by European pharmaceutical partnerships and high-volume nutraceutical encapsulation production capabilities.

Investment Analysis and Opportunities

Investments in the Non-animal Softgel Capsule Market are primarily focused on manufacturing capacity expansion and advanced encapsulation technologies. More than 55% of contract manufacturers are installing additional rotary die encapsulation lines to meet vegetarian capsule demand. Production automation adoption has increased significantly, reducing manual intervention during drying and inspection stages by nearly 35%. Companies are also investing in controlled humidity production rooms, maintaining processing environments between 20% and 30% humidity to improve shell integrity. Approximately 40% of new facility construction projects include dedicated plant-based capsule manufacturing sections. Private-label supplement brands represent a major investment driver. Retailers and e-commerce distributors now require gelatin-free labeling in many product categories, leading procurement departments to sign long-term supply agreements with encapsulation partners. Equipment suppliers report increased orders for multi-material encapsulation systems capable of handling starch and pullulan formulations. Pharmaceutical companies are allocating research budgets toward lipid-based drug delivery technologies, as nearly 40% of new drug candidates demonstrate poor water solubility and require specialized dosage formats.

Emerging markets also present opportunities. Asia and Middle Eastern regions are increasing supplement imports, and more than 50% of newly registered nutraceutical products in certain markets request vegetarian certification. Contract manufacturers are developing export-compliant production lines and halal-certified processing units. Supply chain integration is another investment area, with companies establishing in-house shell polymer production to reduce raw material dependency. Quality testing laboratories are expanding analytical capabilities including dissolution testing and oxygen permeability measurement. These investments are strengthening procurement reliability and expanding the Non-animal Softgel Capsule Market Opportunities across pharmaceutical and nutraceutical supply chains.

New Products Development

Product development activity within the Non-animal Softgel Capsule Market focuses on enhanced bioavailability and consumer convenience. More than 45% of new supplement formulations now incorporate lipid-based carriers such as medium-chain triglyceride oils to improve nutrient absorption. Manufacturers are developing delayed-release softgels designed to protect acid-sensitive ingredients, and laboratory testing shows up to 70% improved ingredient survival through gastric conditions. Multi-phase softgels containing both oil and suspended particles are also being introduced for combination vitamin and mineral delivery. Cosmeceutical supplements are a major innovation area. Beauty nutrition products containing ceramides, carotenoids, and plant collagen alternatives increasingly utilize transparent pullulan capsules. Odor-masking technology has improved significantly, reducing fish oil smell perception by over 60% during consumer testing panels. Pediatric-friendly chewable softgels are also emerging, improving supplement compliance among younger users.

Pharmaceutical developers are introducing softgel formulations for poorly soluble compounds using self-emulsifying systems. Research trials demonstrate absorption improvement up to threefold for certain lipophilic drugs delivered through softgels. Capsule miniaturization is another advancement, allowing easier swallowing for elderly populations. Companies are also creating oxygen-barrier coatings that extend shelf stability for sensitive compounds such as probiotics and antioxidants. These innovations support expanding therapeutic and wellness product categories across the Non-animal Softgel Capsule Market.

Five Recent Developments

• Manufacturing Capacity Expansion: In 2025, a major encapsulation producer added new automated drying tunnels and inspection systems, increasing vegetarian softgel production capacity by approximately 30% while improving quality consistency and reducing shell defects during packaging and transportation handling.
• Advanced Pullulan Technology: A manufacturer introduced high-barrier pullulan shells designed to reduce oxygen permeability by nearly 50%, significantly improving shelf stability of coenzyme Q10 and omega-oil supplements distributed across multiple climate zones.
• Halal Certification Initiative: Several contract manufacturers implemented segregated production lines and certified raw materials, enabling more than 60% of their supplement portfolio to qualify for halal labeling and expanding distribution opportunities in Gulf countries.
• Multi-Fill Softgel Innovation: A new encapsulation system capable of combining oil and suspended nutrients within a single capsule improved dosing convenience, allowing delivery of combination vitamin formulations and reducing daily capsule intake requirements.
• Pharmaceutical Drug Delivery Collaboration: Pharmaceutical developers partnered with encapsulation specialists to evaluate lipid-based softgel drug delivery for solubility-limited compounds, demonstrating improved absorption performance during clinical evaluation studies.

Report Coverage Of Non-animal Softgel Capsule Market

The report evaluates the Non-animal Softgel Capsule Market across material types, applications, and regional production networks. Analysis includes starch, pullulan, and composite polymer capsule technologies and examines adoption across pharmaceutical, nutraceutical, and specialty sectors. The study assesses supply chain structure, raw material sourcing patterns, and manufacturing technologies including rotary die encapsulation and drying tunnel systems. Approximately 65% of analyzed product launches involve health supplements, while pharmaceutical applications represent around 25% and other specialty uses about 10%. Regional coverage spans North America, Europe, Asia-Pacific, and Middle East & Africa, identifying consumption patterns, regulatory influences, and procurement trends. The report also evaluates product performance indicators such as oxygen permeability, disintegration time, and stability in various climatic conditions. Distribution channel analysis includes pharmacies, e-commerce retailers, and private-label brands. The research highlights increasing preference for vegetarian labeling and identifies growing demand for advanced drug delivery systems using lipid-based formulations.

The study further reviews competitive positioning of manufacturers, production capacity distribution, and technology adoption rates. More than half of market participants operate contract manufacturing services for supplement brands, while others focus on pharmaceutical development partnerships. Quality compliance requirements, certification standards, and formulation compatibility factors are analyzed to support procurement and strategic planning decisions. The report provides structured insights into product innovation activity, manufacturing investments, and expanding global adoption of plant-derived encapsulation systems across healthcare and wellness industries.